Merck Announced Topline Results From Two Phase 3 Trials Of Doravirine/Islatravir In Adults With HIV-1 Infection That Is Virologically Suppressed On Different Antiretroviral Therapy Regimens, Trials Met Efficacy Success Criteria For Non-inferiority To Comp
MRKMerck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients
MRKMerck's Phase 3 trial shows subcutaneous pembrolizumab is as effective as IV Keytruda for first-line NSCLC treatment, meeting key pharmacokinetic goals.
Merck Increases Quarterly Dividend From $0.77 To $0.81 Per Share
MRKMerck shares are trading higher after the company reported topline results from its pivotal Phase 3 MK-3475A-D77 trial, which met its dual primary pharmacokinetic endpoints.
MRKMerck Reports Topline Results From Pivotal Phase 3 MK-3475A-D77 Trial; Says Trial Met Its Dual Primary Pharmacokinetic Endpoints
MRKMerck Says European Medicines Agency's Committee for Medicinal Products For Human Use Approves KEYTRUDA (pembrolizumab), Anti-PD-1 Therapy, In Combination With Pemetrexed And Platinum Chemotherapy, For Adult Patients With Unresectable Non-epithelioid Mal
MRKWolfe Research Initiates Coverage On Merck & Co with Peer Perform Rating
MRKMerck Enters Exclusive Global License With LaNova For LM-299, A Novel Investigational PD-1/VEGF Bispecific Antibody; LaNova To Receive Upfront Payment Of $588 And Receive Up To $2.7B In Milestone Payments
MRKGuggenheim Maintains Buy on Merck & Co, Lowers Price Target to $130
MRKWells Fargo Maintains Equal-Weight on Merck & Co, Lowers Price Target to $110
MRKMerck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
MRKMerck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with Winrevair showing promising performance.
BMO Capital Maintains Outperform on Merck & Co, Lowers Price Target to $136
MRKMorgan Stanley Maintains Equal-Weight on Merck & Co, Lowers Price Target to $123
MRKMerck Beats Q3 Estimates, But Lowers Annual Forecast As Gardasil Vaccine Hit By Low China Demand
MRKMerck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.
Merck CEO Says Company Expects To Continue To See A Decline In Gardasil Shipments Into China Into 2025; Says Co Sees 2025 Market Opportunity For Gardasil In China In The $2B To $3B Range, Driven By Opportunity For Use In Males
MRKMerck Expects 2024 Adjusted EPS Of $7.72-$7.77 Compared To Prior Guidance Of $$7.94-$8.04 And Consensus Of $7.74, Outlook Reflects a Net Negative Impact of $0.24/Share Related to Business Development Transactions With Curon Biopharmaceutical and Daiichi S
MRKMerck Expects 2024 Sales Of $63.6B-$64.1B Compared To Prior Guidance Of $63.4B-$64.4B And Consensus Of $64.162B
MRKMerck & Co Q3 2024 Adj EPS $1.57 Beats $1.51 Estimate, Sales $16.66B Beat $16.47B Estimate
MRKPerformance Comparison: Merck & Co And Competitors In Pharmaceuticals Industry
MRKCheck Out What Whales Are Doing With MRK
MRKQurient Announces Collaboration Agreement With MSD To Evaluate Selective CDK7 Inhibitor Q901 In Combination With KEYTRUDA
MRKWhat Are Whales Doing With Merck & Co
MRKSomeone with a lot of money to spend has taken a bullish stance on Merck & Co (NYSE:MRK).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Berenberg Upgrades Merck & Co to Buy, Raises Price Target to $100
MRKMerck Secures Canadian Regulatory Nod For KEYTRUDA In Skin Cancer After Resection
MRKHealth Canada has granted approval for Merck’s (NYSE: MRK) KEYTRUDA (pembrolizumab) for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.
After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff
MRKMerck Announced Health Canada Approved KEYTRUDA as Adjuvant Treatment for Adults and Children with Stage IIB or IIC Melanoma Following Complete Resection
MRKThis Is What Whales Are Betting On Merck & Co
MRKA whale with a lot of money to spend has taken a noticeably bearish stance on Merck & Co.
Looking at options history for Merck & Co (NYSE:MRK) we detected 17 strange trades.
Analyst Ratings for Merck & Co
MRKAnalysts have provided the following ratings for Merck & Co (NYSE:MRK) within the last quarter:
SVB Leerink Maintains Outperform on Merck & Co, Raises Price Target to $109
MRKFive-Year Data For Merck's Keytruda Plus Chemo Shows Sustained Survival Benefit In Lung Cancer Patients
MRKMerck Announced Five-Year Data for KEYTRUDA Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer
MRKMorgan Stanley Maintains Equal-Weight on Merck & Co, Raises Price Target to $87
MRKWhat 7 Analyst Ratings Have To Say About Merck & Co
MRKOver the past 3 months, 7 analysts have published their opinion on Merck & Co (NYSE:MRK) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Biocytogen Reports Antibody Deal With Merck Whereby Co. Will Grant Merck Sole License To Evaluate Proprietary Antibodies Against At Least 3 Distinct Targets With Option To Buy Some Assets At Later Date, No Terms Disclosed
MRKWells Fargo Maintains Overweight on Merck & Co, Raises Price Target to $105
MRKMerck Reports European Commission Approved Co.'s KEYTRUDA For Patients With Microsatellite Instability-High or Deficient Mismatch Repair Tumors in Five Different Types of Cancer
MRKMerck Reports European Commission Approval Of Its KEYTRUDA Plus Chemo
MRKSVB Leerink Maintains Outperform on Merck & Co, Raises Price Target to $102
MRKHearing Investors Business Daily Swingtrader Gives Merck & Co. New Buy Rating
MRKMerck Clocks 50% Q1 Sales Growth Boosted By COVID-19 Treatment, Tightens FY22 EPS Outlook
MRKMerck & Co Raises And Narrows FY22 Adj. EPS Guidance Range From $7.12-$7.27 To $7.24-$7.36 Vs. $7.24 Est.; Co. Raises And Narrows FY22 Sales Guidance From $56.1B-$57.6B To $56.9B-$58.1B Vs. $57.35B Est.
MRKMerck & Co Q1 Adj. EPS $2.14 Beats $1.83 Estimate, Sales $15.90B Beat $14.68B Estimate
MRK